Therapeutic Advances in Neurological Disorders (Nov 2011)

Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?

  • Norman J. Kachuck

DOI
https://doi.org/10.1177/1756285611424461
Journal volume & issue
Vol. 4

Abstract

Read online

No abstracts available.